JP7389134B2 - 脂質組成物 - Google Patents

脂質組成物 Download PDF

Info

Publication number
JP7389134B2
JP7389134B2 JP2021556193A JP2021556193A JP7389134B2 JP 7389134 B2 JP7389134 B2 JP 7389134B2 JP 2021556193 A JP2021556193 A JP 2021556193A JP 2021556193 A JP2021556193 A JP 2021556193A JP 7389134 B2 JP7389134 B2 JP 7389134B2
Authority
JP
Japan
Prior art keywords
group
ethyl
carbon atoms
lipid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556193A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021095876A1 (cg-RX-API-DMAC7.html
Inventor
貴宏 関口
泰輔 遠藤
俊 金海
正樹 野呂
真太郎 田名部
雅彦 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of JPWO2021095876A1 publication Critical patent/JPWO2021095876A1/ja
Priority to JP2023094459A priority Critical patent/JP7566078B2/ja
Application granted granted Critical
Publication of JP7389134B2 publication Critical patent/JP7389134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
JP2021556193A 2019-11-15 2020-11-13 脂質組成物 Active JP7389134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023094459A JP7566078B2 (ja) 2019-11-15 2023-06-08 脂質組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019207118 2019-11-15
JP2019207118 2019-11-15
PCT/JP2020/042513 WO2021095876A1 (ja) 2019-11-15 2020-11-13 脂質組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023094459A Division JP7566078B2 (ja) 2019-11-15 2023-06-08 脂質組成物

Publications (2)

Publication Number Publication Date
JPWO2021095876A1 JPWO2021095876A1 (cg-RX-API-DMAC7.html) 2021-05-20
JP7389134B2 true JP7389134B2 (ja) 2023-11-29

Family

ID=75912395

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556193A Active JP7389134B2 (ja) 2019-11-15 2020-11-13 脂質組成物
JP2023094459A Active JP7566078B2 (ja) 2019-11-15 2023-06-08 脂質組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023094459A Active JP7566078B2 (ja) 2019-11-15 2023-06-08 脂質組成物

Country Status (11)

Country Link
US (1) US20220273817A1 (cg-RX-API-DMAC7.html)
EP (2) EP4059505B1 (cg-RX-API-DMAC7.html)
JP (2) JP7389134B2 (cg-RX-API-DMAC7.html)
KR (4) KR20250057122A (cg-RX-API-DMAC7.html)
CN (2) CN117417265B (cg-RX-API-DMAC7.html)
CA (1) CA3158293C (cg-RX-API-DMAC7.html)
DK (1) DK4328309T3 (cg-RX-API-DMAC7.html)
ES (1) ES3036322T3 (cg-RX-API-DMAC7.html)
FI (1) FI4328309T3 (cg-RX-API-DMAC7.html)
PL (1) PL4328309T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021095876A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964547T3 (es) 2018-06-08 2024-04-08 Fujifilm Corp Compuesto, sal del mismo y partículas lipídicas
CA3143865A1 (en) 2019-06-07 2020-12-10 Fujifilm Corporation Lipid composition
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
PL4332086T3 (pl) * 2021-04-28 2026-06-15 Fujifilm Corporation Związek lub jego sól, cząstki lipidowe, i kompozycja farmaceutyczna
CN114149337B (zh) * 2021-07-07 2022-04-29 天津键凯科技有限公司 一种用于核酸递送的新型可电离脂质及其lnp组合物
CN120420422A (zh) * 2022-01-30 2025-08-05 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
EP4494644A4 (en) * 2022-03-15 2025-06-11 FUJIFILM Corporation LIPID COMPOSITION
JPWO2023176822A1 (cg-RX-API-DMAC7.html) 2022-03-15 2023-09-21
KR20240157096A (ko) * 2022-03-23 2024-10-31 나노베이션 테라퓨틱스 인크. 고 스테롤-함유 지질 나노입자
CA3261789A1 (en) * 2022-07-11 2025-04-25 Fujifilm Corporation COMPOUND AS AN INTERMEDIARY IN THE MANUFACTURE OF AN AMINO LIPID OR A RELATED SALT AND METHOD FOR MANUFACTURE OF AN AMINO LIPID COMPOUND BY MEANS OF THE COMPOUND
CN119677852A (zh) 2022-07-29 2025-03-21 麻省理工学院 抑制信号调节蛋白α(SIRPα)基因表达的组合物和方法
WO2024078614A1 (zh) * 2022-10-13 2024-04-18 深圳深信生物科技有限公司 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒
JP2025537180A (ja) * 2022-11-03 2025-11-14 シャンハイ サーコード バイオメッド カンパニー,リミティド 脂質化合物、脂質ナノ粒子、及び医薬組成物
KR20250129723A (ko) * 2023-01-27 2025-08-29 후지필름 가부시키가이샤 화합물 또는 그 염, 지질 조성물, 의약 조성물 및 송달 캐리어
WO2024190817A1 (ja) 2023-03-13 2024-09-19 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
JPWO2025070702A1 (cg-RX-API-DMAC7.html) * 2023-09-27 2025-04-03
AU2024412236A1 (en) 2023-12-28 2026-07-09 Fujifilm Corporation Method for delivering nucleic acid to immune cells, agent for delivering nucleic acid to immune cells, and use thereof
WO2025143232A1 (ja) * 2023-12-28 2025-07-03 富士フイルム株式会社 免疫細胞への核酸送達剤、および免疫細胞に核酸を送達する方法
WO2025192731A1 (ja) * 2024-03-15 2025-09-18 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
WO2026004829A1 (ja) * 2024-06-24 2026-01-02 富士フイルム株式会社 脂質ナノ粒子の製造方法
WO2026004828A1 (ja) * 2024-06-24 2026-01-02 富士フイルム株式会社 脂質ナノ粒子の製造方法
CN120590341A (zh) * 2025-01-23 2025-09-05 上海环码生物医药有限公司 脂质化合物、脂质纳米颗粒和药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015095340A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2018087753A1 (en) 2016-11-08 2018-05-17 Technology Innovation Momentum Fund (Israel) Limited Partnership Cationic lipids for nucleic acid delivery and preparation thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
JP5288254B2 (ja) 2008-10-17 2013-09-11 株式会社ニコン レンズ系
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
JP2013245107A (ja) 2012-05-29 2013-12-09 Kuma Lift Gijutsu Kenkyusho:Kk 椅子式階段昇降装置
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
DK3221293T3 (da) 2014-11-18 2023-04-03 Arcturus Therapeutics Inc Ioniserbar kationisk lipid til RNA-afgivelse
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
ES2964547T3 (es) * 2018-06-08 2024-04-08 Fujifilm Corp Compuesto, sal del mismo y partículas lipídicas
CA3143865A1 (en) * 2019-06-07 2020-12-10 Fujifilm Corporation Lipid composition
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
JP7518909B2 (ja) * 2020-09-14 2024-07-18 富士フイルム株式会社 脂質組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015095340A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2018087753A1 (en) 2016-11-08 2018-05-17 Technology Innovation Momentum Fund (Israel) Limited Partnership Cationic lipids for nucleic acid delivery and preparation thereof

Also Published As

Publication number Publication date
CN114728016A (zh) 2022-07-08
EP4328309A3 (en) 2024-09-25
CA3158293A1 (en) 2021-05-20
PL4328309T3 (pl) 2025-11-17
JP2023116626A (ja) 2023-08-22
JP7566078B2 (ja) 2024-10-11
JPWO2021095876A1 (cg-RX-API-DMAC7.html) 2021-05-20
WO2021095876A1 (ja) 2021-05-20
EP4328309B1 (en) 2025-07-02
EP4059505B1 (en) 2024-02-21
US20220273817A1 (en) 2022-09-01
KR20250171478A (ko) 2025-12-08
ES3036322T3 (en) 2025-09-17
KR20240090627A (ko) 2024-06-21
CN117417265A (zh) 2024-01-19
KR20250057122A (ko) 2025-04-28
DK4328309T3 (da) 2025-08-18
EP4328309A2 (en) 2024-02-28
CN117417265B (zh) 2026-02-10
EP4059505A4 (en) 2023-01-11
EP4059505A1 (en) 2022-09-21
KR20220082885A (ko) 2022-06-17
CA3158293C (en) 2024-06-25
CN114728016B (zh) 2024-10-29
FI4328309T3 (fi) 2025-09-09

Similar Documents

Publication Publication Date Title
JP7566078B2 (ja) 脂質組成物
JP7241869B2 (ja) 脂質組成物
JP7541151B2 (ja) 化合物またはその塩および脂質粒子
KR20250087641A (ko) 생물 활성 성분을 전달하기 위한 아미노 지질 화합물 및 지질 나노입자
CN114828830A (zh) 药物组合物及处置剂

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231116

R150 Certificate of patent or registration of utility model

Ref document number: 7389134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150